TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03258060

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Temporary pacing study

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Temporary pacing study

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Body Surface Mapping

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Body Surface Mapping
Study: NCT02683668

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Handihaler-Tiotropium 18 mcg untrained
Description: We are looking at the untrained used of Handihaler

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Handihaler-Tiotropium 18 mcg trained
Description: We are looking at the trained use of Handihaler after 14 days treatment

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Respimat-Tiotropium 5 mcg trained
Description: we are looking at the trained use of Respimat after 14 days treatment
Study: NCT00160654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: * Pharmaceutical form: oral tablets~* Concentration: 500 mg~* Route of administration: Oral use
Study: NCT01122108

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholestyramine
Description: Cholestyramine 12 grams, one time dose
Study: NCT02133950

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: elective cryopreservation of available embryos after PGD
Description: no elective fresh embryo transfer; freeze all

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PGD and elective fresh embryo transfer plus cryopreservation of supernumerary available embryos after PGD
Description: PGD and elective fresh embryo transfer plus cryopreservation of supernumerary available embryos after PGD
Study: NCT05028439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Description: All patients underwent biliary sphincterotomy. Cholangiogram was performed to confirm stricture location, length and diameter. The Habib Endo HPB (Hepatobiliary) probe (EMcision, HitchinHerts, UK) was then advanced over a wire at the level of the biliary stricture and ablation using ERBE generator set at 7-10 watts for a time period of 90-120 s was conducted. A 1- to 2-min resting period after energy delivery was allowed before moving the catheter along the length of the stricture to ablate the rest of the stricture. Plastic stent(s) were placed after RFA depending on the location of the malignant obstruction

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: radiofrequency ablation
Description: All patients underwent biliary sphincterotomy. Cholangiogram was performed to confirm stricture location, length and diameter. The Habib Endo HPB (Hepatobiliary) probe (EMcision, HitchinHerts, UK) was then advanced over a wire at the level of the biliary stricture and ablation using ERBE generator set at 7-10 watts for a time period of 90-120 s was conducted. A 1- to 2-min resting period after energy delivery was allowed before moving the catheter along the length of the stricture to ablate the rest of the stricture. Plastic stent(s) were placed after RFA depending on the location of the malignant obstruction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy drug
Description: Gemcitabine 1 000 mg/m2 intravenously on day 1，8; S-1 80 mg/m2 was taken orally twice for two weeks. The curative effect was evaluated comprehensively for each 2 cycles of chemotherapy
Study: NCT01079104

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Therapy
Description: Standard of care treatment
Study: NCT01470209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: BKM120 (20mg to 100mg) will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. BKM120 will be administered on a continuous once daily dosing schedule. Patients should be instructed to take the dose of BKM120 daily in the morning, one hour after a light breakfast (morning meal) at approximately the same time each day. BKM120 should be taken with a glass of water and consumed over as short a time as possible. Patients should swallow the capsules as a whole and not chew them. Patients should continue to fast for 2 hours after the administration of each BKM120 dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: RAD001 will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. RAD001 will be administered orally as once daily dose of 5mg or 10 mg (based on the dose cohort) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take RAD001 in the morning, at the same time each day.
Study: NCT02253966

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisoloneacetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sodium chloride

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride
Study: NCT02356198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EXPAREL
Description: transversus abdominis plane injection
Study: NCT01122108

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colesevelam HCl
Description: Colesevelam HCl, 4 grams, one time dose
Study: NCT02072395

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plication
Description: Plication of the stomach will be performed in conjunction with placement of a gastric band.
Study: NCT02274259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Aflibercept injection is given at every visit. Time to next treatment according to presence of macular edema

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab injection is given at every visit. Time to next treatment according to presence of macular edema
Study: NCT04216407

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: An orthopedic tourniquet was tied to the right lower extremities of the patients in RIPC arm, and tourniquet application was performed before the anhepatic phase in 3 periods of 3 minutes with an interval of 3 minutes.
Study: NCT02223481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbogrel low dose
Study: NCT00455780

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Phase
Description: Weight loss using CBT and meal replacements

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Phase
Description: Weight loss using CBT and meal replacements
Study: NCT02223481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbogrel high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02177838

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy
Description: Undergo EBRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01536483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butyrate enemas
Description: Seven enemas~* Possibility to delay from 24 to 48 hours the procedure in case of clinical poor tolerance(maximum two enemas postponed and delayed at PND12 and PND13)~* The study remains blinded for the investigation team through the intervention of a clinical research nurse~* According to the procedure previously described by Nakaoka et al. (2009), a lubricated Foley catheter Ch 6 will be introduced into the rectum, the balloon will be inflated with 1 ml water for injections. Butyrate solution will be placed in a bag placed 50 cm above the child. Therefore, treatment administration will be performed at a controlled pressure of 50 cm H2O without any manual intervention~* Installation time and retention is setted at 15 minutes~* Treatment units will be directly placed in the incubator 30 min before the procedure to warm the enema to +36°C~* Per-treatment clinical monitoring of the tolerance will be performed by a neonatologist
Study: NCT00845065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: 800 mg, using SCH 503034 200-mg capsules, three times a day (TID) orally (PO) for 48 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 800 mg, using placebo matching SCH 503034 200-mg capsules, three times a day (TID) orally (PO) for 48 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a, pre-filled syringes, given 180 μg/week subcutaneously (SC) for 48 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a, pre-filled syringes, given 180 μg/week subcutaneously (SC) for 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin 200-mg capsules, weight-based dosing~* \<75 kg, 1000 mg/day orally (PO), divided twice daily (BID)~* \>=75 kg, 1200 mg/day PO, divided BID~for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin 200-mg capsules, weight-based dosing~* \<75 kg, 1000 mg/day orally (PO), divided twice daily (BID)~* \>=75 kg, 1200 mg/day PO, divided BID~for 48 weeks
Study: NCT01198509

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: doxycycline - 100 mg twice per day, for 2 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vancomycin
Description: vancomycin, 250 mg four times a day, for 2 weeks
Study: NCT01908088

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell transplantation
Description: autologous transplantation of cultured fibroblast on amniotic membrane in patients with Epidermolysis Bullosa with mitten hands.
Study: NCT03825159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Orthosis with an Integrated System of Electric Surface Stimulation and Heat Sensing
Description: The electrical stimulation technology integrated with the total contact spinal orthosis combines the external correction forces on the spinal skeleton from the passive orthosis with the muscle forces at the lateral trunk from the stimulation process.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: spinal orthosis
Description: The ventrally opened total contact spinal orthosis will be designed and made of Copolymer and Aliplast. Correcting pressure points have to use the pressure pads at relevant points.
Study: NCT04391452

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stress Resist® (oral dietary supplement)
Description: Stress Resist® (dietary supplement) is composed of Mg (150 mg), Vitamin B6 (0.7 mg), Vitamin B9 (100µg), Vitamin B12 (1.25 µg), rhodiola (222mg), and green tea/L-théanine (125 mg). Oral supplementation. All subjects in the MAGRITTE study will receive either a dietary supplement or a placebo for 28 days (morning intake). The effects on stress will be studied both with questionnaires, biological samples (blood, urine and stool), with a Heart Rate Variability test. 40 subjects (20 subjects per group) will have an fMRI exam.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Stress Resist® (oral dietary supplement)
Description: Stress Resist® (dietary supplement) is composed of Mg (150 mg), Vitamin B6 (0.7 mg), Vitamin B9 (100µg), Vitamin B12 (1.25 µg), rhodiola (222mg), and green tea/L-théanine (125 mg). Oral supplementation. All subjects in the MAGRITTE study will receive either a dietary supplement or a placebo for 28 days (morning intake). The effects on stress will be studied both with questionnaires, biological samples (blood, urine and stool), with a Heart Rate Variability test. 40 subjects (20 subjects per group) will have an fMRI exam.
Study: NCT02117349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raplixa
Description: Raplixa is a biological product approved for use in adults to help control bleeding from small blood vessels when standard surgical techniques, such as suture, ligature or cautery, are ineffective or impractical. When applied to a bleeding site, Raplixa is dissolved in the blood and a reaction starts between the fibrinogen and thrombin proteins. This results in the formation of blood clots to help stop the bleeding.
Study: NCT00455780

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continued CBT
Description: Using CBT during weight loss maintenance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continued CBT
Description: Using CBT during weight loss maintenance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continued CBT
Description: Using CBT during weight loss maintenance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continued CBT
Description: Using CBT during weight loss maintenance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: reduced energy density education
Description: Additional nutritional learning

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: reduced energy density education
Description: Additional nutritional learning

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: continued use of meal replacements
Description: continued use of meal replacements during weight loss maintenance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: continued use of meal replacements
Description: continued use of meal replacements during weight loss maintenance
Study: NCT05791357

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PCR (Polymerase Chain Reaction) targeting the 16 ribosomal DNA
Description: Molecular diagnostic using a broad range PCR on obtained histological material (native valve/valve prosthesis/fragments of them)
Study: NCT03180320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BESMILE-HF program
Description: The following activities will be conducted as part of the BESMILE-HF program:~1. Baduanjin exercise;~2. evaluations of exercise capacity and clinical conditions;~3. consultations on exercise prescription and management of symptoms/signs during exercise;~4. education covering topics related to the CHF and exercise; and~5. a series of adherence strategies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Usual medications
Description: Throughout the study period, all participants will receive typical Western medications for chronic heart failure, according to national guidelines.

Intervention type: DRUG
Group type: OTHER
Intervention: Usual medications
Description: Throughout the study period, all participants will receive typical Western medications for chronic heart failure, according to national guidelines.
Study: NCT00346294

Intervention type: DRUG
Group type: OTHER
Intervention: Etanercept
Description: Intervention type was to study the drug delivery method.
Study: NCT04421105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysergic acid diethylamide (LSD) 5µg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysergic acid diethylamide (LSD) 10µg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysergic acid diethylamide (LSD)20 µg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03452059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AiLegs, AiWalker and HKAFO
Description: 5 days. Using their own control method, each morning using AiLegs, AiWalker AiWalker and HKAFO for 6 minutes walk test, three kinds of appliance between at least 30 minutes to determine heart rate, blood pressure and breathing back to quiet level. Repeat the same procedure in the afternoon ，the order is also random. Each participant will complete 10 groups of lower limb exoskeleton rehabilitation Training robot (including AiLegs, AiWalker two models) and HKAFO 6 minutes walking test

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AiLegs, AiWalker and HKAFO
Description: 5 days. Using their own control method, each morning using AiLegs, AiWalker AiWalker and HKAFO for 6 minutes walk test, three kinds of appliance between at least 30 minutes to determine heart rate, blood pressure and breathing back to quiet level. Repeat the same procedure in the afternoon ，the order is also random. Each participant will complete 10 groups of lower limb exoskeleton rehabilitation Training robot (including AiLegs, AiWalker two models) and HKAFO 6 minutes walking test
Study: NCT03744533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: head-down position treatment
Description: the head position of subjects is lowered to 20 degrees in a supine position between 8:00-22:00 within 24h post-randomization as long as possible. During the procedure, when subjects feel intolerable, the head position will be elevated to lying flat (0 degree) for 5-10min, and then the above procedure is repeated. After 24h post-randomization, the head down procedures with -20 degrees in a supine position with duration of 1-1.5 hour will be performed three times daily at 9:00-11:00, 15:00-17:00 and 20:00-22:00, respectively.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: guideline-based treatment
Description: guideline-based treatment
Study: NCT03469206

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: intra-arterial thrombectomy
Description: It is the emergency surgical removal of emboli which are blocking blood circulation. It usually involves removal of thrombi (blood clots)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intra-arterial thrombectomy
Description: It is the emergency surgical removal of emboli which are blocking blood circulation. It usually involves removal of thrombi (blood clots)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous thrombolysis
Description: alteplase is used in the intravenous thrombolysis. It catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown.
Study: NCT02041533

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Study: NCT03744533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: guideline-based treatment
Description: guideline-based treatment
Study: NCT02117349

Intervention type: DEVICE
Group type: OTHER
Intervention: Gelfoam
Description: Gelfoam Sterile Sponge is a medical device (USP, Pfizer) intended for application to bleeding surfaces as a hemostatic. It is a water-insoluble, off-white, nonelastic, porous, pliable product. It may be cut without fraying, used wet or dry, and is able to absorb many times its weight in blood and other fluids.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelfoam
Description: Gelfoam Sterile Sponge is a medical device (USP, Pfizer) intended for application to bleeding surfaces as a hemostatic. It is a water-insoluble, off-white, nonelastic, porous, pliable product. It may be cut without fraying, used wet or dry, and is able to absorb many times its weight in blood and other fluids.

Intervention type: DRUG
Group type: OTHER
Intervention: Rescue treatment
Description: Thrombin-containing hemostats included in standard care at the site

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue treatment
Description: Thrombin-containing hemostats included in standard care at the site
Study: NCT01762995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg
Description: One tablet ( 50 mg) will be administered orally as a single dose in each period per the random code

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg
Description: One tablet ( 50 mg) will be administered orally as a single dose in each period per the random code

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate 1200 mg
Description: Two tablets (2 X 600 mg) will be administered orally as a single dose in three out of four periods to Cohort 1 only per the random code. Calcium carbonate will be given in fasted state, fed state and 2 hours before dolutegravir administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous Fumarate 324 mg
Description: One tablet (324 mg) will be administered orally as a single dose in three out of four periods to Cohort 2 only per the random code. Ferrous fumarate will be given in fasted state, fed state and 2 hours before dolutegravir administration.
Study: NCT00590577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 25 mg eq.
Description: Paliperidone palmitate 150 mg eq. i.m. Day 1 and 25 mg eq. i.m. Days 8, 36, 64

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 150 mg eq.
Description: Paliperidone palmitate 150 mg eq. i.m. Days 1, 8, 36, 64

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo i.m. Days 1, 8, 36, 64

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 100 mg eq.
Description: Paliperidone palmitate 150 mg eq. i.m. Day 1 and 100 mg eq. i.m. Days 8, 36, 64
Study: NCT02752464

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Up to 12 sessions of behavioral counseling using motivational interviewing techniques focused on diet and physical activity behaviors over a 12 week period. Counselors will be guided in their sessions by a computer program called CuesWeight. Participants also receive text messages to enable participants to track their behaviors; this information is relayed to the counselors to inform the counseling sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: feedback report
Description: All participants receive a brief printed feedback report displaying their current levels of nutrition and physical activity behaviors and tips for meeting recommended guidelines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: feedback report
Description: All participants receive a brief printed feedback report displaying their current levels of nutrition and physical activity behaviors and tips for meeting recommended guidelines.
Study: NCT01805388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Regeneration Treatment Group
Description: Regenerative Root Canal Therapy using Triple Antibiotic Paste study drug

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control Non-Study Drug Group
Description: Endodontic RTC with no study drug